Pharmacokinetic evaluation of almotriptan for the treatment of migraines

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 5, 2013, Pages 637-644

  Negro, Andrea ^a   Lionetto, Luana ^a   D'Alonzo, Lidia ^a   Casolla, Barbara ^a   Marsibilio, Francesco ^a   Vignaroli, Gabriele ^a   Simmaco, Maurizio ^a   Martelletti, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Almotriptan; Migraine; Pharmacodynamics; Pharmacokinetics; Triptans

Indexed keywords

ALMOTRIPTAN; ELETRIPTAN; FLUOXETINE; FROVATRIPTAN; ITRACONAZOLE; KETOCONAZOLE; MOCLOBEMIDE; NARATRIPTAN; PLACEBO; PROPRANOLOL; RIZATRIPTAN; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 1E RECEPTOR; SEROTONIN 1F RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SUMATRIPTAN; VERAPAMIL; ZOLMITRIPTAN;

ANALGESIC ACTIVITY; BINDING AFFINITY; CENTRAL NERVOUS SYSTEM DISEASE; DIZZINESS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEART DISEASE; HUMAN; MAXIMUM PLASMA CONCENTRATION; MENSTRUAL MIGRAINE; MIGRAINE; NAUSEA; NONHUMAN; PARESTHESIA; PREGNANCY; QUALITY OF LIFE; REVIEW; SEROTONIN SYNDROME; SOMNOLENCE; SYSTEMATIC REVIEW; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; VASOCONSTRICTION; VOMITING; XEROSTOMIA;

CLINICAL TRIALS AS TOPIC; DRUG EVALUATION; DRUG INTERACTIONS; DRUG TOLERANCE; HUMANS; MIGRAINE DISORDERS; PAIN; TRYPTAMINES;

EID: 84876394836     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.783012     Document Type: Review

References (80)

1. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 201. Lancet 2012;380(9859):2163-96
2. Steiner TJ, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. J Headache Pain 2013;14:1
3. Martelletti P, Birbeck GL, Katsarava Z, et al. The Global Burden of Disease survey 2010, lifting the burden and thinking outside-the-box on headache disorders. J Headache Pain 2013;14:13
4. Negro A, Rocchietti-March M, Fiorillo M, et al. Chronic migraine: current concepts and ongoing treatments. Eur Rev Med Pharmacol Sci 2011;15:1401-20
5. Negro A, Martelletti P. Chronic migraine plus medication overuse headache: two entities or not? J Headache Pain 2011;12:593-601
6. Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/ 1D receptor agonists. Arch Neurol 2002;59:1084-8
7. Link AS, Kuris A, Edvinsson L. Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system. J Headache Pain 2008;9:5-12
8. Hamel E. Serotonin and migraine: biology and clinical implications. Cephalalgia 2007;27:1295-300
9. Tepper J, Stillman J. What is the best drug-delivery approach for the acute treatment of migraine? Expert Rev Neurother 2012;12:253-5 1
10. Calatayud-Pascual MA, Balaguer-Fernández C, Serna-Jiménez CE, et al. Effect of iontophoresis on in vitro transdermal absorption of almotriptan. Int J Pharm 2011;416(1):189-94 1
11. Gentile G, Borro M, Lala N, et al. Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine. J Headache Pain 2010;11:431-5 1
12. Gentile G, Missori S, Borro M, et al. Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine. J Headache Pain 2010;11:151-6 1
13. Bou J, Domenech T, Puig J, et al. Pharmacological characterizacion of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine. Eur J Pharmacol 2000;410:33-41 1
14. Sandrini G, Perrotta A, Buscone S, et al. Almotriptan in the treatment of migraine. Neuropsychiatr Dis Treat 2007;3(6):799-809 1
15. Gras J, Bou J, Llenas J, et al. Functional profile of almotriptan in animal models predictive of antimigraine activity. Eur J Pharmacol 2000;410:43-51 1
16. Bou J, Gras J, Cortijo J, et al. Vascular effects of the new antimigraine agent almotriptan on human cranial and peripheral arteries. Cephalalgia 2001;21:804-12 1
17. Jansat JM, Costa J, Salsa P, et al. Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healty male volunteers. J Clin Pharmacol 2002;42:1303-10 1
18. Gras J, Lleans J, Jansat JM, et al. Almotriptan, a new antimigraine agent: a review. CNS Drug Rev 2002;8:217-34 1
19. Ferrari A, Tiraferri I, Neri L, et al. Why pharmacokinetic differences among oral triptans have little clinical importance: a comment. J Headache Pain 2011;12(1):5-12 2
20. Baldwin JR, Fleishaker JC, Azie NE, et al. A comparison of the pharmacokinetics and tolerability of the anti-migraine compound almotriptan in healthy adolescents and adults. Cephalalgia 2004;24:288-92 2
21. Salva M, Jansat JM, Martinez-Tobed A, et al. Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos 2003;31:404-11 2
22. Dodick DW. A review of the clinical efficacy and tolerability of almotriptan in acute migraine. Expert Opin Pharmacother 2003;4:1157-63 2
23. Jansat JM, Martinez-Tobed A, Garcia E, et al. Effect of food intake on the bioavailability of almotriptan, an antimigraine compound, in healthy volunteers: an open, randomized, crossover, single-dose clinical trial. Int J Clin Pharmacol Ther 2006;44:185-90 2
24. Cabarrocas X, Salva M, Pavesi M, et al. Ethanol does not significantly affect the bioavailability of almotriptan: an open, randomized, crossover, single-dose, phase I clinical trial in healthy volunteers. Int J Clin Pharmacol Ther 2006;44:443-8 2
25. Fleishaker JC, Ryan KK, Carel BJ, et al. Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. J Clin Pharmacol 2001;41:217-23 2
26. Fleishaker JC, Ryan KK, Jansat JM, et al. Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. Br J Clin Pharmacol 2001;51:437-41 2
27. Fleishaker JC, Sisson TA, Carel BJ, et al. Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers. Cephalalgia 2001;21:61-5 2
28. Fleishaker JC, Sisson TA, Carel BJ, et al. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. Clin Pharmacol Ther 2000;67:498-503 2
29. Fleishaker JC, Herman BD, Carel BJ, et al. Interaction between ketoconazole and almotriptan in healthy volunteers. J Clin Pharmacol 2003;43:423-7 3
30. Sclar DA, Robison LM, Castillo LV, et al. Concomitant use of triptan, and SSRI or SNRI after the US Food and Drug Administration alert on serotonin syndrome. Headache 2012;52(2):198-203 3
31. Dahlof C, Tfelt-Hansen P, Massiou H, et al. Almotriptan Study Group. Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine. Neurology 2001;57:1811-17 3
32. Dahlof CG, Pascual J, Dodick DW, Dowson AJ. Efficacy, speed of action and tolerability of almotriptan in theacute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials. Cephalalgia 2006;26(4):400-8 3
33. Pascual J, Falk RM, Piessens F, et al. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia 2000;20:588-96 3
34. Pascual J, Falk R, Docekal R, et al. Tolerability and efficacy of almotriptan in the long-term treatment of migraine. Eur Neurol 2001;45:206-13 3
35. Cabarrocas X, Esbri R, Peris F, et al. Long-term efficacy and safety of oral almotriptan: interim analysis of a 1-year open study. Headache 2001;41:57-62 3
36. Linder SL, Mathew NT, Cady RK, et al. Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial. Headache 2008;48:1326-36 3
37. Berenson F, Vasconcellos E, Pakalnis A, et al. Long-term, open-label safety study of oral almotriptan 12.5 mg for the acute treatment of migraine in adolescents. Headache 2010;50:795-807 3
38. Diamond ML, Cady RK, Mao L, et al. Characteristics of migraine attacks and responses to almotriptan treatment: a comparison of menstrually related and nonmenstrually related migraines. Headache 2008;48:248-58 3
39. Allais G, Acuto G, Cabarrocas X, et al. Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurol Sci 2006;27(Suppl 2):S193-7 4
40. Allais G, Bussone G, D'Andrea G, et al. Almotriptan 12.5 mg in menstrually related migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2011;31:144-51 4
41. Bartolini M, Giamberardino MA, Lisotto C, et al. Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study. J Headache Pain 2012;13:401-6 4
42. Allais G, Acuto G, Benedetto C, et al. Evolution of migraine-associated symptoms in menstrually related migraine following symptomatic treatment with almotriptan. Neurol Sci 2010;31(Suppl 1):S115-19 4
43. Bussone G, Allais G, Castagnoli Gabellari I, et al. Almotriptan for menstrually related migraine. Expert Opin Pharmacother 2011;12:1933-43 4
44. Lionetto L, Fiorillo M, Martelletti P. Efficacy and tolerability of almotriptan in menstrual migraine: a comment. Expert Opin Pharmacother 2011;12:2279-81 4
45. Pascual J, Diener HC. Use of almotriptan in triptan-experienced and triptan-naïve patients. Curr Med Res Opin 2007;23:2433-40 4
46. Bermejo PE, Dorado R, Gomez-Arguelles JM. Variation in almotriptan effectiveness according to different prophylactic treatments. Headache 2009;49:1277-82 4
47. Mathew NT. Early intervention with almotriptan improves sustained pain-free response in acute migraine. Headache 2003;43:1075-9 4
48. Goadsby PJ, Zanchin G, Geraud G, et al. Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia 2008;28:383-91 4
49. Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 2002;42:28-31 5
50. Dowson AJ, Massiou H, Lainez JM, et al. Almotriptan improves response rates when treatment is within 1 hour of migraine onset. Headache 2004;44:318-22 5
51. Freitag FG, Finlayson G, Rapoport AM, et al. AIMS Investigators. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS). Headache 2007;47:519-30 5
52. Mathew NT, Finlayson G, Smith TR, et al. AEGIS Investigator Study Group. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study). Headache 2007;47:189-98 5
53. Díaz-Insa S, Goadsby PJ, Zanchin G, et al. The impact of allodynia on the efficacy of almotriptan when given early in migraine: data from the "Act when mild" study. Int J Neurosci 2011;121:655-61 5
54. Freitag F, Smith T, Mathew N, et al. AEGIS Investigator Study Group. Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial. Headache 2008;48:341-54 5
55. Lanteri-Minet M, Díaz-Insa S, Leone M, et al. START Study. Efficacy of almotriptan in early intervention for treatment of acute migraine in a primary care setting: the START study. Int J Clin Pract 2010;64:936-43 5
56. Leone M, Vila C, McGown C. Influence of trigger factors on the efficacy of almotriptan as early intervention for the treatment of acute migraine in a primary care setting: the START study. Expert Rev Neurother 2010;10:1399-408 5
57. Spierings EL, Gomez-Mancilla B, Grosz DE, et al. Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison. Arch Neurol 2001;58:944-50 5
58. Dowson AJ, Massiou H, Laínez JM, et al. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. Cephalalgia 2002;22:453-61 5
59. Cady R. Almotriptan reduces the incidence of migraine-associated symptoms: a pooled analysis. Headache 2002;42(Suppl 1):26-31 6
60. Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22:633-58 6
61. Dodick DW, Sandrini G, Williams P. Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine. CNS Drugs 2007;21:73-82 6
62. Goadsby PJ, Massiou H, Pascual J, et al. Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurol Scand 2007;115:34-40 6
63. Bartolini M, Giamberardino MA, Lisotto C, et al. A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. J Headache Pain 2011;12:361-8 6
64. Chen LC, Ashcroft DM. Meta-analysis examining the efficacy and safety of almotriptan in the acute treatment of migraine. Headache 2007;47:1169-77 6
65. Dodick DW. Oral almotriptan in the treatment of migraine: safety and tolerability. Headache 2001;41:449-55 6
66. Dodick DW, Martin V. Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms. Cephalalgia 2004;24:417-24 6
67. Lewis DW. Almotriptan for the acute treatment of adolescent migraine. Expert Opin Pharmacother 2010;11:2431-6 6
68. Colman SS, Brod MI, Krishnamurthy A, et al. Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. Clin Ther 2001;23:127-45 6
69. Diener HC. Consistent efficacy, tolerability, and high levels of satisfaction with almotriptan 12.5 mg when used to treat multiple migraine attacks in routine clinical practice. Headache 2005;45:624-31 7
70. Díaz-Insa S, Vila C, McGown CC. Improved patient satisfaction and pain evolution with almotriptan in migraine: a primary care study. Curr Med Res Opin 2011;27:559-67 7
71. Wang JT, Barr CE, Goldfarb SD. Impact of chest pain on cost of migraine treatment with almotriptan and sumatriptan. Headache 2002;42(Suppl 1):38-43 7
72. Geraud G, Keywood C, Senard JM. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 2003;43:376-88 7
73. Sarchielli P, Granella F, Prudenzano MP, et al. Italian guidelines for primary headaches: 2012 revised version. J Headache Pain 2012;13(Suppl 2):31-70 7
74. Corbelli I, Caproni S, Eusebi P, et al. Drug-dependence behaviour and outcome of medication-overuse headache after treatment. J Headache Pain 2012;13(8):653-60 7
75. De Felice M, Ossipov MH, Wang R, et al. Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers. Brain 2010;133(Pt 8):2475-88 7
76. Dodick D, Lipton RB, Martin V, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine. Headache 2004;44:414-25 7
77. Negro A, Lionetto L, Simmaco M, Martelletti P. CGRP receptor antagonists: an expanding drug class for acute migraine? Expert Opin Investig Drugs 2012;21:807-18 7
78. Lionetto L, Negro A, Palmisani S, et al. Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opin Emerg Drugs 2012;17(3):393-406 7
79. Saxena PR, Tfelt-Hansen P. Triptans, 5HT1B/1D agonists in the acute treatment of migraine In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, editors. The headaches. 3rd edition, 200. pp. 469-503 8
80. Saxena PR, Tfelt-Hansen P. Success and failure of triptans. J Headaches 2001;2:3-11